trending Market Intelligence /marketintelligence/en/news-insights/trending/sIq0XvvLGwdDmkDCbdd-0A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Alterity drug wins EU orphan-drug tag for Parkinson's-like disorder

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Alterity drug wins EU orphan-drug tag for Parkinson's-like disorder

Alterity Therapeutics Ltd. said the European Commission granted an orphan-drug designation to PBT434 for treating a neurodegenerative disorder called multiple system atrophy.

Multiple system atrophy, or MSA, is a rare, degenerative neurological disorder that affects the body's involuntary functions, including blood pressure, breathing, bladder function and muscle control. It is a form of atypical Parkinson's, where patients present symptoms similar to Parkinson's but do not respond to therapy.

Under the designation, the Australian biotechnology company will have market exclusivity in the EU for 10 years, subject to regulatory approval. Additionally, Alterity will be eligible for benefits such as assistance in developing clinical trials, reduced fees and access to research grants.

The European Medicines Agency's Committee for Orphan Medicinal Products recommended PBT434 for the designation in November 2019.

The U.S. Food and Drug Administration granted orphan-drug designation to PBT434 to treat MSA.